🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,187 results for “Takeda” Clear

  1. Mezagitamab, Placebo matching for Mezagitamab

    Takeda Pharmaceuticals International AG

    Chronic Primary Immune Thrombocytopenia

    phase 3 small molecule active

    1 trial

  2. Mixed salts of a single-entity amphetamine

    Takeda Pharmaceuticals International AG

    Attention Deficit Disorder With Hyperactivity

    phase 3 small molecule completed

    1 trial

  3. Mixed salts of a single-entity amphetamine (ADDERALL XR)

    Takeda Pharmaceuticals International AG

    ADHD

    phase 3 small molecule completed

    1 trial

  4. Motesanib

    Takeda Pharmaceuticals International AG

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule terminated

    1 trial

  5. NE-58095 IR

    Takeda Pharmaceuticals International AG

    Involutional Osteoporosis

    phase 3 small molecule completed

    1 trial

  6. NPSP558

    Takeda Pharmaceuticals International AG

    Hypoparathyroidism

    phase 3 small molecule completed

    3 trials

  7. Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulphate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.

    Takeda Pharmaceuticals International AG

    Attention Deficit Disorder With Hyperactivity

    phase 3 small molecule completed

    4 trials

  8. OBI-1

    Takeda Pharmaceuticals International AG

    Acquired Hemophilia A

    phase 3 mab completed

    1 trial

  9. OBI-1

    Takeda Pharmaceuticals International AG

    Hemophilia A

    phase 3 mab terminated

    1 trial

  10. Ontamalimab

    Takeda Pharmaceuticals International AG

    Crohn's Disease

    phase 3 mab terminated

    3 trials

  11. Ontamalimab

    Takeda Pharmaceuticals International AG

    Ulcerative Colitis

    phase 3 small molecule terminated

    3 trials

  12. Oral Budesonide Suspension (OBS)

    Takeda Pharmaceuticals International AG

    Eosinophilic Esophagitis (EoE)

    phase 3 small molecule completed

    2 trials

  13. Orteronel

    Takeda Pharmaceuticals International AG

    Prostate Cancer

    phase 3 small molecule completed

    3 trials

  14. Otezla 10mg, 20mg, 30 mg film-coated tablets, Matching Placebo for TAK-279 Dose A, ZASOCITINIB, ZASOCITINIB, Matching Placebo for TAK-279 Dose B, Otezla 10mg, 20mg, 30 mg film-coated tablets, Matching Placebo for Apremilast, Otezla 10mg, 20mg, 30 mg film-coated tablets

    Takeda Pharmaceuticals International AG

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  15. Otezla 10mg, 20mg, 30 mg film-coated tablets, Otezla 10mg, 20mg, 30 mg film-coated tablets, Apremilast placebo (same excipient as over-encapsulated Otezla), Otezla 10mg, 20mg, 30 mg film-coated tablets, ZASOCITINIB, Otezla 30 mg film-coated tablets, TAK-279 placebo (same excipient as TAK-279)

    Takeda Pharmaceuticals International AG

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  16. Otezla 30 mg film-coated tablets, Otezla 10mg, 20mg, 30 mg film-coated tablets, TAK-279 placebo (same excipient as TAK-279), Otezla 10mg, 20mg, 30 mg film-coated tablets, Otezla 10mg, 20mg, 30 mg film-coated tablets, Apremilast placebo (same excipient as over-encapsulated Otezla), ZASOCITINIB

    Takeda Pharmaceuticals International AG

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  17. PEGylated Recombinant Factor VIII

    Takeda Pharmaceuticals International AG

    Hemophilia A

    phase 3 mab completed

    2 trials

  18. PEGylated Recombinant factor VIII (rFVIII)

    Takeda Pharmaceuticals International AG

    Hemophilia A

    phase 3 mab completed

    1 trial

  19. PONATINIB, PONATINIB, Ponatinib, IMATINIB, IMATINIB

    Takeda Pharmaceuticals International AG

    Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

    phase 3 small molecule active

    1 trial

  20. PREDNISONE, Entyvio 300 mg powder for concentrate for solution for infusion

    Takeda Pharmaceuticals International AG

    Active Ulcerative Colitis (UC) or Crohn's disease (CD)

    phase 3 small molecule active

    1 trial

  21. PREDNISONE, Entyvio 300 mg powder for concentrate for solution for infusion

    Takeda Pharmaceuticals International AG

    Moderately to severely active Ulcerative Colitis (UC)

    phase 3 small molecule active

    1 trial

  22. PREDNISONE, Entyvio 300 mg powder for concentrate for solution for infusion, BUDESONIDE

    Takeda Pharmaceuticals International AG

    Moderately to severely active Crohn's disease (CD)

    phase 3 small molecule active

    1 trial

  23. PTH/Calcium

    Takeda Pharmaceuticals International AG

    Osteoporosis

    phase 3 small molecule completed

    1 trial

  24. Pantoprazole

    Takeda Pharmaceuticals International AG

    GERD

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources